This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, January 24, 2023 Forty years ago ...
By Nigel Rawson and John Adams, November 23, 2022 For seven years, the Patented Medicines Prices Review Board (PMPRB) – ...
This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, November 2, 2022 This month marks ...
By Nigel Rawson and John Adams, May 2, 2022 On April 14, 2022, Health Minister Jean-Yves Duclos announced the federal ...
This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, April 22, 2022 After being late to ...
OTTAWA, ON (April 11, 2022): We are pleased to announce that Nigel Rawson and John Adams will be joining the ...
By Nigel Rawson and John Adams, March 24, 2022 Much has been written over the last few years about the ...
This article originally appeared in the Financial Post. Below is an excerpt from the article, which can be read in ...
This article originally appeared in the Hamilton Spectator. By Nigel Rawson, February 23, 2022 Theatre of the Absurd features plays ...
A new MLI commentary warns that pending and aggressive drug price control efforts could lead to major unintended consequences in ...
Canadians have heard little from any political party in the election campaign about how they will improve access to innovative medicines ...
Advocates for national pharmacare who insist on control of drug prices, not by negotiation but by federal regulation, may have ...
